What is the 13F Pro Quality Score for GCTK?

13F Pro ranks Glucotrack, Inc. (GCTK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GCTK's current score at https://13fpro.ai/company/GCTK (free sign-up required for the full ranking).

Which hedge funds own the most GCTK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GCTK include HRT FINANCIAL, JANE STREET GROUP,, CITADEL ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/GCTK as soon as new 13F filings post.

Where does 13F Pro source GCTK data?

All Glucotrack, Inc. fundamentals and ownership data come directly from SEC EDGAR. Glucotrack, Inc. files with the SEC under CIK 1506983. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GCTK in?

Glucotrack, Inc. (GCTK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GCTK research updated on 13F Pro?

GCTK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Glucotrack, Inc.(GCTK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1506983 GCTK stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 19 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

GCTK Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Glucotrack, Inc. (GCTK), a Healthcare sector company. GCTK is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 19 institutional filers currently hold this stock. Top institutional holders of GCTK by reported 13-F value include HRT FINANCIAL, JANE STREET GROUP, CITADEL ADVISORS, based on the most recent SEC filings. GCTK trades on the Nasdaq exchange and files with the SEC under CIK 1506983. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GCTK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Glucotrack, Inc. directly from SEC EDGAR.

✦

Fun facts about Glucotrack, Inc.

Quirks, history, and lore behind GCTK — the kind of stuff that makes a stock memorable.

1
The Basics
A micro-cap medical device company · listed on Nasdaq · headquartered in New Jersey · focused squarely on chronic disease monitoring.
2
The Numbers
With a market cap in the tens of millions and minimal revenue, this is an early-stage developer — the kind of company that runs on R&D spend and hope.
3
The History
The company has spent years developing a sensor technology designed to move glucose monitoring away from the painful, repetitive finger-prick that diabetics know all too well.
4
The Secret
Its core technology aims to measure blood glucose continuously from inside a blood vessel rather than under the skin — a fundamentally different approach from most CGM competitors.
5
The Lore
The device is designed to be implanted near the jugular vein, paired with an external reader — aiming for accuracy that wrist-worn and patch-style continuous glucose monitors struggle to match.
6
The Giveaway
Its very name is a portmanteau of glucose and tracking, and its ticker — GCTK — leaves absolutely nothing to the imagination.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-3.8M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

+14.2% YoY

$-19.4MFY 2025

FY22 $-4.4MFY23 $-7.1MFY24 $-22.6MFY25 $-19.4M

Operating Income

-10.6% YoY

$-16.1MFY 2025

FY22 $-4.4MFY23 $-7.1MFY24 $-14.5MFY25 $-16.1M

EPS (Diluted)

-99.2% YoY

$31.22FY 2025

FY22 $0.29FY23 $34.18FY24 $4106.00FY25 $31.22

Total Assets

+32.1% YoY

$7.8MFY 2025

FY22 $2.4MFY23 $4.9MFY24 $5.9MFY25 $7.8M

Op. Cash Flow

-22.0% YoY

$-15.2MFY 2025

FY22 $-3.7MFY23 $-6.6MFY24 $-12.5MFY25 $-15.2M

Free Cash Flow

-21.8% YoY

$-15.3MFY 2025

FY22 $-3.7MFY23 —FY24 $-12.6MFY25 $-15.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-19.4M +14.2%	$-22.6M -218.4%	$-7.1M -60.0%	$-4.4M -9.0%	$-4.1M -50.9%	$-2.7M
Operating Income	$-16.1M -10.6%	$-14.5M -104.8%	$-7.1M -60.3%	$-4.4M -9.7%	$-4.0M -29.0%	$-3.1M
EPS (Diluted)	$31.22 -99.2%	$4106.00 +11912.9%	$34.18 +11686.2%	$0.29 +11.5%	$0.26 +36.8%	$0.19
Total Assets	$7.8M +32.1%	$5.9M +20.9%	$4.9M +101.2%	$2.4M -61.1%	$6.3M -40.9%	$10.6M
Operating Cash Flow	$-15.2M -22.0%	$-12.5M -90.5%	$-6.6M -75.9%	$-3.7M +1.1%	$-3.8M -7.7%	$-3.5M
Free Cash Flow	$-15.3M -21.8%	$-12.6M	—	$-3.7M +1.2%	$-3.8M -6.2%	$-3.6M

Get alerted when GCTK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Glucotrack, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GCTK

HRT FINANCIAL LP
$65.0K205,442 sh
JANE STREET GROUP, LLC
$41.0K128,459 sh
CITADEL ADVISORS LLC
$25.4K79,530 sh
Ikarian Capital, LLC
$14.6K45,830 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.9K34,207 sh
Virtu Financial LLC
$6.0K18,726 sh
GRANITE ISLANDS PRIVATE WEALTH, LLC
$5.0K15,700 sh
BOOTHBAY FUND MANAGEMENT, LLC
$4.3K13,525 sh
UBS Group AG
$4.3K13,343 sh
CITIGROUP INC
$4.1K12,872 sh

Fund	Value	Shares
HRT FINANCIAL LP	$65.0K	205,442
JANE STREET GROUP, LLC	$41.0K	128,459
CITADEL ADVISORS LLC	$25.4K	79,530
Ikarian Capital, LLC	$14.6K	45,830
GEODE CAPITAL MANAGEMENT, LLC	$10.9K	34,207
Virtu Financial LLC	$6.0K	18,726
GRANITE ISLANDS PRIVATE WEALTH, LLC	$5.0K	15,700
BOOTHBAY FUND MANAGEMENT, LLC	$4.3K	13,525
UBS Group AG	$4.3K	13,343
CITIGROUP INC	$4.1K	12,872

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GCTK on your watchlist

Track score changes the day Glucotrack, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GCTK a good stock to buy?

13F Pro's AI-powered analysis of Glucotrack, Inc. (GCTK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GCTK are available on the GCTK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GCTK is classified as a small company.

Which hedge funds own GCTK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GCTK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Glucotrack, Inc.'s investment landscape.